IPHA
NASDAQ
$1.72
Innate Pharma (IPHA)
Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6 (+248.84%)
Market Cap
$165M
Free Cash Flow Yield
-64.27%
Beta (5Y)
0.61
Price Chart
Valuation
Market Cap$165M
P/S18.77
P/B20.10
Profitability
Total Revenue (TTM)$1.14M
Gross Profit (TTM)-$40M
EBITDA-$125M
Operating Margin-690%
EPS-$1.32
Financial Health
Debt-to-Equity-104%
Free Cash Flow Yield-64.27%
Growth & Risk
EPS 5Y CAGR+1.02%
Revenue 5Y CAGR-61.35%
FCF 5Y CAGR-5.58%
Beta (5Y)0.61
Sharpe Ratio0.31